Skip to content
10-K

Annual Report

Atara Biotherapeutics, Inc. ATRA

0001193125-26-108361

← back to feed
Filed
Mar 16, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 10, 2026 8.18M sh
Shares Diluted FY 2025 · Dec 31, 2025 12.72M sh
Shares Diluted FY 2025 · Dec 31, 2024 7.49M sh
Capex FY 2025 · Dec 31, 2025 $0
Capex FY 2025 · Dec 31, 2024 $246K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$50.94M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$68.72M
Short Term Investments FY 2025 · Dec 31, 2025 $0
Short Term Investments FY 2025 · Dec 31, 2024 $17.47M
Cash And Equivalents FY 2025 · Dec 31, 2025 $8.48M
Cash And Equivalents FY 2025 · Dec 31, 2024 $25.03M
Stockholders Equity FY 2025 · Dec 31, 2025 −$38.5M
Stockholders Equity FY 2025 · Dec 31, 2024 −$97.28M
Stockholders Equity restated FY 2025 · Dec 31, 2023 $99.23M
Current Liabilities FY 2025 · Dec 31, 2025 $14.92M
Current Liabilities FY 2025 · Dec 31, 2024 $134.57M
Total Liabilities FY 2025 · Dec 31, 2025 $58.74M
Total Liabilities FY 2025 · Dec 31, 2024 $206.38M
Current Assets FY 2025 · Dec 31, 2025 $12.21M
Current Assets FY 2025 · Dec 31, 2024 $64.89M
Total Assets FY 2025 · Dec 31, 2025 $20.24M
Total Assets FY 2025 · Dec 31, 2024 $109.1M
Eps Diluted FY 2025 · Dec 31, 2025 $2.57
Eps Diluted FY 2025 · Dec 31, 2024 −$11.41
Eps Basic FY 2025 · Dec 31, 2025 $2.61
Eps Basic FY 2025 · Dec 31, 2024 −$11.41
Sga Expense FY 2025 · Dec 31, 2025 $26.25M
Sga Expense FY 2025 · Dec 31, 2024 $39.89M
Rd Expense FY 2025 · Dec 31, 2025 $37.45M
Rd Expense FY 2025 · Dec 31, 2024 $151.48M
Net Income FY 2025 · Dec 31, 2025 $32.69M
Net Income FY 2025 · Dec 31, 2024 −$85.4M
Operating Income FY 2025 · Dec 31, 2025 $35.86M
Operating Income FY 2025 · Dec 31, 2024 −$83.44M
Revenue FY 2025 · Dec 31, 2025 $120.77M
Revenue FY 2025 · Dec 31, 2024 $128.94M